IOVANCE BIOTHERAPEUTICS, INC. Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised
IOVANCE BIOTHERAPEUTICS, INC. (IOVA) reported Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised of $2.41 million for the 12-month period ending 2023-12-31, per its 10-K filed 2024-02-28.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans · last filed 2024-02-28
- IOVANCE BIOTHERAPEUTICS, INC. proceeds, issuance of shares, share-based payment arrangement, excluding option exercised for the quarter ending 2023-12-31 was $1.14M, a 6.15% increase year-over-year.
- IOVANCE BIOTHERAPEUTICS, INC. proceeds, issuance of shares, share-based payment arrangement, excluding option exercised for the quarter ending 2023-09-30 was $0.00.
- IOVANCE BIOTHERAPEUTICS, INC. proceeds, issuance of shares, share-based payment arrangement, excluding option exercised for the quarter ending 2022-12-31 was $1.07M, a 74.19% increase year-over-year.
- IOVANCE BIOTHERAPEUTICS, INC. proceeds, issuance of shares, share-based payment arrangement, excluding option exercised for the quarter ending 2022-09-30 was $0.00, a 100.00% decline year-over-year.
- IOVANCE BIOTHERAPEUTICS, INC. proceeds, issuance of shares, share-based payment arrangement, excluding option exercised for fiscal 2023 was $2.41M, a 45.62% increase from fiscal 2022.
- IOVANCE BIOTHERAPEUTICS, INC. proceeds, issuance of shares, share-based payment arrangement, excluding option exercised for fiscal 2022 was $1.66M, a 4.35% increase from fiscal 2021.
- IOVANCE BIOTHERAPEUTICS, INC. proceeds, issuance of shares, share-based payment arrangement, excluding option exercised for fiscal 2021 was $1.59M.
| Period end | Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised 3 month | Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised 6 month | Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised 9 month | Proceeds, Issuance of Shares, Share-based Payment Arrangement, Excluding Option Exercised 12 month |
|---|---|---|---|---|
| 2023-12-31 | $1.14M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $1.14M derived: sum of 2 quarters · filed 2024-02-28 | $2.41M 10-K · filed 2024-02-28 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $1.27M 10-Q · filed 2023-11-07 | ||
| 2023-06-30 | $1.27M 10-Q · filed 2023-08-08 | |||
| 2022-12-31 | $1.07M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $1.07M derived: sum of 2 quarters · filed 2024-02-28 | $1.66M 10-K · filed 2024-02-28 | |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $582.00K 10-Q · filed 2023-11-07 | ||
| 2022-06-30 | $582.00K 10-Q · filed 2023-08-08 | |||
| 2021-12-31 | $616.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $1.59M derived: sum of 2 quarters · filed 2024-02-28 | $1.59M 10-K · filed 2024-02-28 | |
| 2021-09-30 | $970.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $970.00K 10-Q · filed 2022-11-03 | ||
| 2021-06-30 | $0.00 10-Q · filed 2022-08-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |